Molecular Weight(MW): 443.31
Selinexor (KPT-330) is an orally bioavailable selective CRM1 inhibitor. Phase 2.
Cited by 7 Publications
3 Customer Reviews
Bortezomib and KPT330 enhance apoptosis in HCT116 and RKO cells. A, HCT116 and RKO cells were treated with bortezomib, KPT330, or their combination for 48 hours at the indicated concentrations. The cells were subsequently stained with Annexin V, apoptotic cells were distinguished by flow cytometric analysis. B, Measurement of caspase-3 and -7 by means of a luminometric assay was performed in cells receiving the same treatment.
Mol Cancer Ther, 2017, 16(4):717-728. Selinexor (KPT-330) purchased from Selleck.
Purity & Quality Control
Choose Selective CRM1 Inhibitors
|Description||Selinexor (KPT-330) is an orally bioavailable selective CRM1 inhibitor. Phase 2.|
As the clinical candidate analog of KPT-185, KPT-330 exhibits similar effects on the viability of T-ALL cells and elicits rapid apoptotic response. KPT-330 also reduces cell growth in MOLT-4, Jurkat, HBP-ALL, KOPTK-1, SKW-3, and DND-41 cell lines, with IC50 values of 34-203 nM. 
|In vivo||KPT-330 dramatically suppresses the growth of T-ALL cells (MOLT-4) and AML cells (MV4–11) in vivo, with little toxicity to normal haematopoietic cells.  In SCID mice with diffuse human MM bone lesions, KPT-330 inhibits MM-induced bone lysis and prolongs survival. Moreover, KPT-330 directly impairs osteoclastogenesis and bone resorption by blocking RANKL-induced NF-κB and NFATc1, with minimal impact on osteoblasts and BMSCs. |
|In vitro||DMSO||88 mg/mL (198.5 mM)|
|Ethanol||40 mg/mL (90.23 mM)|
|In vivo||Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+49% PEG 300+ddH2O
For best results, use promptly after mixing.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02471911||Recruiting||Diffuse Large B-Cell Lymphoma||Weill Medical College of Cornell University|Karyopharm Therapeutics Inc||November 2015||Phase 1|
|NCT02228525||Active not recruiting||Myelodysplastic Syndromes||Memorial Sloan Kettering Cancer Center|M.D. Anderson Cancer Center|Columbia University|Karyopharm Therapeutics Inc||August 27 2014||Phase 2|
|NCT02213133||Terminated||Squamous Cell Carcinoma||Karyopharm Therapeutics Inc||July 2014||Phase 2|
|NCT02091245||Active not recruiting||Relapsed Acute Lymphoblastic Leukemia (ALL)|Refractory Acute Lymphoblastic Leukemia (ALL)|Relapsed Acute Myelogenous Leukemia (AML)|Refractory Acute Myelogenous Leukemia (AML)|Relapsed Mixed Lineage Leukemia|Refractory Mixed Lineage Leukemia|Relapsed Biphenotypic Leukemia|Refractory Biphenotypic Leukemia|Chronic Myelogenous Leukemia (CML) in Blast Crisis||Dana-Farber Cancer Institute|William Lawrence and Blanche Hughes Foundation|Karyopharm Therapeutics Inc||March 2014||Phase 1|
|NCT02078349||Recruiting||Solid Tumors||National University Hospital Singapore|Karyopharm Therapeutics Inc||February 2014||Phase 1|
|NCT01607905||Completed||Solid Tumor||Karyopharm Therapeutics Inc||June 2012||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.